%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Thiam, M.
%A Diop-Ndiaye, H.
%A Diouf, A. D.
%A Vidal, Nicole
%A Ndiaye, O.
%A Ndiaye, I.
%A Ngom-Gueye, N. F.
%A Diallo, S.
%A Diongue, O. D.
%A Camara, M.
%A Seck, A.
%A Mboup, S.
%A Toure-Kane, C.
%T HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system
%D 2013
%L PAR00010187
%G ENG
%J Journal of Clinical Microbiology
%@ 0095-1137
%K SENEGAL
%M ISI:000314108000028
%N 2
%P 578-584
%R 10.1128/jcm.02452-12
%U https://www.documentation.ird.fr/hor/PAR00010187
%> https://www.documentation.ird.fr/intranet/publi/2022-12/010087035.pdf
%V 51
%W Horizon (IRD)
%X In this study, we investigated the prevalence of human immunodeficiency virus type 1 (HIV-1) drug resistance mutations and genetic variability among Senegalese patients undergoing highly active antiretroviral therapy (ART) in the public health system. We conducted a cross-sectional study of 72 patients with suspected therapeutic failure. HIV-1 genotyping was performed with Viroseq HIV-1 Genotyping System v2.0 or the procedure developed by the ANRS AC11 resistance study group, and a phylogenetic analysis was performed. The median follow-up visit was at 40 (range, 12 to 123) months, and the median viral load was 4.67 (range, 3.13 to 6.94) log(10) copies/ml. The first-line therapeutic regimen was nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz (EFV) or NRTIs plus nevirapine (NVP) (54/72 patients; 75%), and the second-line therapy was NRTIs plus a protease inhibitor (PI/r) (18/72; 25%). Fifty-five patients (55/72; 76.39%) had at least one drug resistance mutation. The drug resistance rates were 72.22 and 88.89% for the first-line and second-line ARTs, respectively. In NRTI mutations, thymidine analog mutations (TAMs) were found in 50.79% and the M184V mutation was found in 34.92% of the samples. For non-NRTI resistance, we noted a predominance of the K103N mutation (46.27%). For PI/r, several cases of mutations were found with a predominance of M46I and L76V/F at 24% each. The phylogenetic analysis revealed CRF02_AG as the predominant circulating recombinant form (43/72; 59.72%). We found a high prevalence of resistance mutations and a high rate of TAMs among Senegalese patients in the public health system. These findings emphasize the need to improve virological monitoring in resource-limited settings.
%$ 052 ; 050